Systematic  ||| S:0 E:11 ||| JJ
review  ||| S:11 E:18 ||| NN
and  ||| S:18 E:22 ||| CC
mixed  ||| S:22 E:28 ||| JJ
treatment  ||| S:28 E:38 ||| NN
comparison  ||| S:38 E:49 ||| NN
of  ||| S:49 E:52 ||| IN
randomized  ||| S:52 E:63 ||| JJ
evidence  ||| S:63 E:72 ||| NN
for  ||| S:72 E:76 ||| IN
empirical ||| S:76 E:85 ||| NN
,  ||| S:85 E:87 ||| ,
pre-emptive  ||| S:87 E:99 ||| JJ
and  ||| S:99 E:103 ||| CC
directed  ||| S:103 E:112 ||| JJ
treatment  ||| S:112 E:122 ||| NN
strategies  ||| S:122 E:133 ||| NNS
for  ||| S:133 E:137 ||| IN
invasive  ||| S:137 E:146 ||| FW
mould  ||| S:146 E:152 ||| FW
disease  ||| S:152 E:160 ||| FW
Randomized  ||| S:160 E:171 ||| FW
controlled  ||| S:171 E:182 ||| FW
trials  ||| S:182 E:189 ||| FW
( ||| S:189 E:190 ||| -LRB-
RCTs ||| S:190 E:194 ||| NNP
)  ||| S:194 E:196 ||| -RRB-
provide  ||| S:196 E:204 ||| VB
the  ||| S:204 E:208 ||| DT
most  ||| S:208 E:213 ||| RBS
reliable  ||| S:213 E:222 ||| JJ
estimates  ||| S:222 E:232 ||| NNS
of  ||| S:232 E:235 ||| IN
the  ||| S:235 E:239 ||| DT
effects  ||| S:239 E:247 ||| NNS
of  ||| S:247 E:250 ||| IN
treatments ||| S:250 E:260 ||| NNS
.  ||| S:260 E:262 ||| .
However ||| S:262 E:269 ||| RB
,  ||| S:269 E:271 ||| ,
not  ||| S:271 E:275 ||| RB
all  ||| S:275 E:279 ||| DT
treatments  ||| S:279 E:290 ||| NNS
are  ||| S:290 E:294 ||| VBP
compared  ||| S:294 E:303 ||| VBN
in  ||| S:303 E:306 ||| IN
available  ||| S:306 E:316 ||| JJ
RCTs ||| S:316 E:320 ||| NN
,  ||| S:320 E:322 ||| ,
making  ||| S:322 E:329 ||| VBG
comparison  ||| S:329 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
treatments  ||| S:343 E:354 ||| JJ
problematic ||| S:354 E:365 ||| NN
.  ||| S:365 E:367 ||| .
Mixed  ||| S:367 E:373 ||| JJ
treatment  ||| S:373 E:383 ||| NN
comparisons  ||| S:383 E:395 ||| NNS
( ||| S:395 E:396 ||| -LRB-
MTCs ||| S:396 E:400 ||| NNP
)  ||| S:400 E:402 ||| -RRB-
can  ||| S:402 E:406 ||| MD
provide  ||| S:406 E:414 ||| VB
estimates  ||| S:414 E:424 ||| NNS
of  ||| S:424 E:427 ||| IN
the  ||| S:427 E:431 ||| DT
comparative  ||| S:431 E:443 ||| JJ
effects  ||| S:443 E:451 ||| NNS
of  ||| S:451 E:454 ||| IN
treatments  ||| S:454 E:465 ||| NNS
across  ||| S:465 E:472 ||| IN
a  ||| S:472 E:474 ||| DT
range  ||| S:474 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
available  ||| S:483 E:493 ||| JJ
therapeutic  ||| S:493 E:505 ||| JJ
options ||| S:505 E:512 ||| NNS
.  ||| S:512 E:514 ||| .
MTCs  ||| S:514 E:519 ||| JJ
use  ||| S:519 E:523 ||| NN
networks  ||| S:523 E:532 ||| NNS
of  ||| S:532 E:535 ||| IN
available  ||| S:535 E:545 ||| JJ
direct  ||| S:545 E:552 ||| JJ
comparisons  ||| S:552 E:564 ||| NNS
to  ||| S:564 E:567 ||| TO
estimate  ||| S:567 E:576 ||| VB
differences  ||| S:576 E:588 ||| NNS
in  ||| S:588 E:591 ||| IN
treatments  ||| S:591 E:602 ||| NNS
that  ||| S:602 E:607 ||| WDT
have  ||| S:607 E:612 ||| VBP
not  ||| S:612 E:616 ||| RB
been  ||| S:616 E:621 ||| VBN
estimated  ||| S:621 E:631 ||| VBN
in  ||| S:631 E:634 ||| IN
trials  ||| S:634 E:641 ||| NNS
via  ||| S:641 E:645 ||| IN
a  ||| S:645 E:647 ||| DT
common  ||| S:647 E:654 ||| JJ
comparator ||| S:654 E:664 ||| NN
.  ||| S:664 E:666 ||| .
We  ||| S:666 E:669 ||| PRP
conducted  ||| S:669 E:679 ||| VBD
a  ||| S:679 E:681 ||| DT
systematic  ||| S:681 E:692 ||| JJ
review  ||| S:692 E:699 ||| NN
and  ||| S:699 E:703 ||| CC
MTCs  ||| S:703 E:708 ||| JJ
of  ||| S:708 E:711 ||| IN
comparative  ||| S:711 E:723 ||| JJ
RCTs  ||| S:723 E:728 ||| NN
in  ||| S:728 E:731 ||| IN
haematological  ||| S:731 E:746 ||| JJ
patients  ||| S:746 E:755 ||| NNS
of  ||| S:755 E:758 ||| IN
anti-mould  ||| S:758 E:769 ||| JJ
active  ||| S:769 E:776 ||| JJ
agents  ||| S:776 E:783 ||| NNS
used  ||| S:783 E:788 ||| VBN
for  ||| S:788 E:792 ||| IN
the  ||| S:792 E:796 ||| DT
empirical  ||| S:796 E:806 ||| JJ
treatment  ||| S:806 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
febrile  ||| S:819 E:827 ||| JJ
neutropenia  ||| S:827 E:839 ||| NNS
( ||| S:839 E:840 ||| -LRB-
Analysis  ||| S:840 E:849 ||| NNP
1 ||| S:849 E:850 ||| CD
) ||| S:850 E:851 ||| -RRB-
,  ||| S:851 E:853 ||| ,
and  ||| S:853 E:857 ||| CC
pre-emptive  ||| S:857 E:869 ||| JJ
therapy  ||| S:869 E:877 ||| NN
( ||| S:877 E:878 ||| -LRB-
Analysis  ||| S:878 E:887 ||| NNP
2 ||| S:887 E:888 ||| CD
)  ||| S:888 E:890 ||| -RRB-
of  ||| S:890 E:893 ||| IN
invasive  ||| S:893 E:902 ||| JJ
mould  ||| S:902 E:908 ||| JJ
diseases ||| S:908 E:916 ||| NNS
.  ||| S:916 E:918 ||| .
In  ||| S:918 E:921 ||| IN
addition ||| S:921 E:929 ||| NN
,  ||| S:929 E:931 ||| ,
we  ||| S:931 E:934 ||| PRP
summarized  ||| S:934 E:945 ||| VBD
the  ||| S:945 E:949 ||| DT
evidence  ||| S:949 E:958 ||| NN
available  ||| S:958 E:968 ||| JJ
associated  ||| S:968 E:979 ||| VBN
with  ||| S:979 E:984 ||| IN
the  ||| S:984 E:988 ||| DT
use  ||| S:988 E:992 ||| NN
of  ||| S:992 E:995 ||| IN
directed  ||| S:995 E:1004 ||| JJ
treatment  ||| S:1004 E:1014 ||| NN
strategies  ||| S:1014 E:1025 ||| NNS
( ||| S:1025 E:1026 ||| -LRB-
Analysis  ||| S:1026 E:1035 ||| NNP
3 ||| S:1035 E:1036 ||| CD
) ||| S:1036 E:1037 ||| -RRB-
.  ||| S:1037 E:1039 ||| .
For  ||| S:1039 E:1043 ||| IN
empirical  ||| S:1043 E:1053 ||| JJ
therapy ||| S:1053 E:1060 ||| NN
,  ||| S:1060 E:1062 ||| ,
caspofungin  ||| S:1062 E:1074 ||| VBD
proved  ||| S:1074 E:1081 ||| VBN
superior  ||| S:1081 E:1090 ||| JJ
to  ||| S:1090 E:1093 ||| TO
amphotericin  ||| S:1093 E:1106 ||| VB
B ||| S:1106 E:1107 ||| NNP
,  ||| S:1107 E:1109 ||| ,
liposomal  ||| S:1109 E:1119 ||| FW
amphotericin  ||| S:1119 E:1132 ||| FW
B ||| S:1132 E:1133 ||| NNP
,  ||| S:1133 E:1135 ||| ,
amphotericin  ||| S:1135 E:1148 ||| JJ
B  ||| S:1148 E:1150 ||| NN
lipid  ||| S:1150 E:1156 ||| NN
complex  ||| S:1156 E:1164 ||| NN
and  ||| S:1164 E:1168 ||| CC
voriconazole  ||| S:1168 E:1181 ||| NN
in  ||| S:1181 E:1184 ||| IN
the  ||| S:1184 E:1188 ||| DT
outcome  ||| S:1188 E:1196 ||| NN
of  ||| S:1196 E:1199 ||| IN
survival ||| S:1199 E:1207 ||| NN
,  ||| S:1207 E:1209 ||| ,
but  ||| S:1209 E:1213 ||| CC
no  ||| S:1213 E:1216 ||| DT
agents  ||| S:1216 E:1223 ||| NNS
showed  ||| S:1223 E:1230 ||| VBD
superiority  ||| S:1230 E:1242 ||| VBN
for  ||| S:1242 E:1246 ||| IN
treatment  ||| S:1246 E:1256 ||| NN
response ||| S:1256 E:1264 ||| NN
.  ||| S:1264 E:1266 ||| .
There  ||| S:1266 E:1272 ||| EX
was  ||| S:1272 E:1276 ||| VBD
no  ||| S:1276 E:1279 ||| DT
evidence  ||| S:1279 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
a  ||| S:1291 E:1293 ||| DT
difference  ||| S:1293 E:1304 ||| NN
between  ||| S:1304 E:1312 ||| IN
pre-emptive  ||| S:1312 E:1324 ||| JJ
and  ||| S:1324 E:1328 ||| CC
empirical  ||| S:1328 E:1338 ||| JJ
strategies  ||| S:1338 E:1349 ||| NNS
on  ||| S:1349 E:1352 ||| IN
mortality  ||| S:1352 E:1362 ||| NN
outcomes ||| S:1362 E:1370 ||| NNS
.  ||| S:1370 E:1372 ||| .
For  ||| S:1372 E:1376 ||| IN
directed  ||| S:1376 E:1385 ||| JJ
therapy ||| S:1385 E:1392 ||| NN
,  ||| S:1392 E:1394 ||| ,
voriconazole  ||| S:1394 E:1407 ||| NN
was  ||| S:1407 E:1411 ||| VBD
superior  ||| S:1411 E:1420 ||| JJ
to  ||| S:1420 E:1423 ||| TO
amphotericin  ||| S:1423 E:1436 ||| VB
B  ||| S:1436 E:1438 ||| NNP
for  ||| S:1438 E:1442 ||| IN
overall  ||| S:1442 E:1450 ||| JJ
survival ||| S:1450 E:1458 ||| NN
,  ||| S:1458 E:1460 ||| ,
and  ||| S:1460 E:1464 ||| CC
both  ||| S:1464 E:1469 ||| DT
voriconazole  ||| S:1469 E:1482 ||| NN
and  ||| S:1482 E:1486 ||| CC
liposomal  ||| S:1486 E:1496 ||| JJ
amphotericin  ||| S:1496 E:1509 ||| JJ
B  ||| S:1509 E:1511 ||| NNP
were  ||| S:1511 E:1516 ||| VBD
superior  ||| S:1516 E:1525 ||| JJ
to  ||| S:1525 E:1528 ||| TO
amphotericin  ||| S:1528 E:1541 ||| VB
B  ||| S:1541 E:1543 ||| NNP
and  ||| S:1543 E:1547 ||| CC
amphotericin  ||| S:1547 E:1560 ||| JJ
B  ||| S:1560 E:1562 ||| NN
colloidal  ||| S:1562 E:1572 ||| NN
dispersion  ||| S:1572 E:1583 ||| NN
on  ||| S:1583 E:1586 ||| IN
the  ||| S:1586 E:1590 ||| DT
outcome  ||| S:1590 E:1598 ||| NN
of  ||| S:1598 E:1601 ||| IN
response ||| S:1601 E:1609 ||| NN
.  ||| S:1609 E:1611 ||| .
While  ||| S:1611 E:1617 ||| IN
limited  ||| S:1617 E:1625 ||| JJ
to  ||| S:1625 E:1628 ||| TO
some  ||| S:1628 E:1633 ||| DT
degree  ||| S:1633 E:1640 ||| NN
by  ||| S:1640 E:1643 ||| IN
the  ||| S:1643 E:1647 ||| DT
availability  ||| S:1647 E:1660 ||| NN
of  ||| S:1660 E:1663 ||| IN
RCTs ||| S:1663 E:1667 ||| NNP
,  ||| S:1667 E:1669 ||| ,
the  ||| S:1669 E:1673 ||| DT
MTCs  ||| S:1673 E:1678 ||| NN
reported  ||| S:1678 E:1687 ||| VBD
here  ||| S:1687 E:1692 ||| RB
provide  ||| S:1692 E:1700 ||| VB
the  ||| S:1700 E:1704 ||| DT
best  ||| S:1704 E:1709 ||| RBS
available  ||| S:1709 E:1719 ||| JJ
evidence  ||| S:1719 E:1728 ||| NN
of  ||| S:1728 E:1731 ||| IN
relative  ||| S:1731 E:1740 ||| JJ
therapeutic  ||| S:1740 E:1752 ||| JJ
success  ||| S:1752 E:1760 ||| NN
for  ||| S:1760 E:1764 ||| IN
different  ||| S:1764 E:1774 ||| JJ
available  ||| S:1774 E:1784 ||| JJ
treatment  ||| S:1784 E:1794 ||| NN
strategies ||| S:1794 E:1804 ||| NNS
.  ||| S:1804 E:1806 ||| .
